Key takeaways:
- Clinicians should build patient timelines that map symptom onset against medication changes, life stage transitions, and environmental factors—recognizing that bladder symptoms in postpartum and perimenopausal patients almost always reflect overlapping contributions rather than a single cause.
- Microplastics have been identified in placental tissue, maternal blood, and breast milk, suggesting fetal and neonatal exposure occurs, although long-term clinical implications are still being studied; counseling should focus on practical exposure reduction without inducing shame or fear.
- A biopsychosocial approach that accounts for the lived experience of the individual—not just clinical diagnoses and drug lists—produces better bladder health outcomes than a reductive single-cause framework.
Bladder symptoms in patients seeing ob-gyns rarely have a single cause—and sorting through the overlapping contributions of medications, hormonal shifts, pelvic floor dysfunction, and environmental exposures requires a framework that is as much biographical as it is clinical, according to Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, the founder of the Fosnight Center for Sexual Health and a medical advisor for Aeroflow Urology.
Fosnight described her approach to multifactorial bladder symptom evaluation as built around a timeline.
"I encourage clinicians to build timelines with their patients—when did these symptoms occur, what medications changed, what life stages are they in, what environmental or lifestyle factors could also be contributing," she said. The categories she considers simultaneously include hormonal shifts, medications, pelvic floor dysfunction, genitourinary syndrome of menopause, mental health, sleep disruption, and inflammatory exposures.
"The best care happens when we stop looking for a single culprit and really start recognizing bladder health as multifactorial," she said.
This framework is particularly relevant in postpartum and perimenopausal patients, where multiple physiologic and pharmacologic changes often coincide. Anticholinergics, antidepressants, and hormonal therapies can each independently affect bladder function, and their effects may compound or obscure one another when layered on top of underlying pelvic floor changes or hormonal transitions. Fosnight emphasized a biopsychosocial lens—one that accounts for the lived experience of the individual patient, not just the sum of her diagnoses and medications.
On the question of microplastic and nanoplastic exposure—an area of growing patient concern, particularly during pregnancy—Fosnight struck a tone of informed reassurance over alarm.
"Pregnancy is a time for informed reduction, not panic," she said. Research has identified microplastics in placental tissues, maternal blood, and breast milk, suggesting that fetal and neonatal exposure likely occurs, though the long-term clinical implications remain under study. For patients who ask about reducing exposure, Fosnight recommended a practical, non-shaming approach: Avoid heating food in plastic containers, prioritize fresh foods when possible, improve indoor ventilation, and reduce unnecessary single-use plastic exposure.
"Pregnant patients already carry enormous pressure," she said. "Our role as providers is to offer realistic, evidence-informed guidance without creating shame or fear."
The through line across both areas—bladder symptom evaluation and environmental exposure counseling—is the same clinical posture: Resist the impulse to simplify, meet patients where they are, and provide guidance that is actionable rather than overwhelming.
